• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on June 2, 2025June 2, 2025

Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever

Brighton Collaboration Releases New Template for Evaluating VSV-Based Lassa Fever Vaccines The Brighton Collaboration is proud to...
Read More
Posted on May 27, 2025May 27, 2025

Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine Congress

This April, global leaders in immunization, public health, and biotechnology convened in Washington, D.C. for the 2025 World Vacci...
Read More
Posted on June 21, 2023August 3, 2023

AESI Case Definition Companion Guide: Spontaneous Abortion and Ectopic Pregnancy

This deliverable collates into a single document the SPEAC Spontaneous Abortion and Ectopic Pregnancy  resources, including the I...
Read More
Posted on April 5, 2023June 27, 2023

BC Template: Viral Vector Vaccines (Chinese translation)

This post contains the Chinese translation of the Brighton Collaboration template for viral vector vaccines, developed by the Vira...
Read More
Posted on March 24, 2023August 3, 2023

European Medicines Agency Myocarditis Workshop Report (January 2023)

In January 2023, the European Medicines Agency (EMA) hosted a workshop on myocarditis post-COVID vaccination. This workshop review...
Read More
Posted on March 12, 2023August 3, 2023

Sensorineural Hearing Loss AESI

This post contains the Companion Guide for Sensorineural Hearing Loss (SNHL). This and other companion guides have been created as...
Read More
Posted on August 18, 2022August 3, 2023

Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services

Brighton Collaboration is very excited to announce that the Clinical Infectious Diseases, Volume 75, Issue Supplement 1, 15 Augu...
Read More
Posted on April 29, 2022August 3, 2023

Understanding Vaccine Safety and the Roles of the FDA and the CDC – NEJM article

The New England Journal of Medicine published the following review article on April 28th, 2022: Understanding Vaccine Safety and...
Read More
Posted on April 25, 2022August 3, 2023

ACIP Meeting Report – April 20th 2022

The ACIP met on April 20th to consider recommendations for a 2nd booster dose of mRNA COVID-19 vaccines. To download the CDC AC...
Read More
Posted on April 13, 2022August 3, 2023

Science News Piece on Vaccine Safety (GVDN, INSIS)

Science posted an article on April 12th titled” Pandemic propels global effort to study rare vaccine side effects”. The articl...
Read More
1 2 3 Next page

Recent Posts

  • Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa feverJune 2, 2025
  • Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine CongressMay 27, 2025
  • Brighton Collaboration News — May 2025May 19, 2025
  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy